DK2956482T3 - Behandling af perifert t-cellelymfom - Google Patents

Behandling af perifert t-cellelymfom Download PDF

Info

Publication number
DK2956482T3
DK2956482T3 DK14704576.9T DK14704576T DK2956482T3 DK 2956482 T3 DK2956482 T3 DK 2956482T3 DK 14704576 T DK14704576 T DK 14704576T DK 2956482 T3 DK2956482 T3 DK 2956482T3
Authority
DK
Denmark
Prior art keywords
nkp46
antibody
ptcl
cells
antibodies
Prior art date
Application number
DK14704576.9T
Other languages
English (en)
Inventor
Cécile Bonnafous
Hélène Sicard
Mathieu Blery
Renaud Buffet
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Application granted granted Critical
Publication of DK2956482T3 publication Critical patent/DK2956482T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (14)

1. Antistof, der binder et NKp46-polypeptid og udtømmer NKp46-udtrykkende tumorceller, til anvendelse til behandling eller forebyggelse af et perifert T-cellelymfom (PTCL) hos en person.
2. Forbindelse til anvendelse ifølge krav 1, hvor personen har en orto-visceral ekstranodal PTCL.
3. Forbindelse til anvendelse ifølge krav 2, hvor den orto-viscerale ekstranodale sygdom er NK/T-lymfom.
4. Forbindelse til anvendelse ifølge krav 2, hvor den orto-viscerale ekstranodale sygdom er enteropatiforbundet T-cellelymfom (EATL).
5. Forbindelse ifølge krav 1, hvor personen har anaplastisk storcellet lymfom (ALCL).
6. Forbindelse til anvendelse ifølge krav 1, hvor PTCL er et NK/T-lymfom, nasal type, og hvor anvendelsen ikke kræver et trin med bestemmelse af NKp46-polypeptidstatus af maligne celler hos personen, der har et PTCL, før administration af et antistof, der binder et NKp46-polypeptid.
7. Forbindelse til anvendelse ifølge kravene 1 til 5, hvor behandlingen eller forebyggelsen af et PTCL hos en person omfatter: a) bestemmelse af NKp46-polypeptidstatus af maligne celler hos personen, der har et PTCL, og b) ved en bestemmelse af, at et NKp46-polypeptid udtrykkes på overfladen af et væsentligt antal af de maligne celler, administrering til personen af antistoffet, der binder et NKp4 6-polypeptid.
8. Forbindelse til anvendelse ifølge krav 7, hvor bestemmelse af NKp46-polypeptidstatus omfatter bestemmelse af, om et NKp46-polypeptid udtrykkes på overfladen af et væsentligt antal af de maligne celler.
9. Forbindelse til anvendelse ifølge krav 8, hvor bestemmelse af, om et NKp46-polypeptid udtrykkes på overfladen af de maligne celler, omfatter opnåelse fra personen af en biologisk prøve, der omfatter PTCL-celler, etablering af kontakt mellem cellerne og et antistof, der binder et NKp46-polypeptid, og påvisning af celler, der udtrykker NKp46.
10. Forbindelse til anvendelse ifølge krav 1, hvor antistoffet omfatter en konstant region af human IgGl eller IgG3.
11. Forbindelse til anvendelse ifølge krav 1 eller 10, hvor antistoffet omfatter en modificeret Fc-konstant region.
12. Forbindelse til anvendelse ifølge krav 1, 10 eller 11, hvor antistoffet omfatter en aminosyremodifikation, der øger binding til en human Fcy-receptor.
13. Forbindelse til anvendelse ifølge et hvilket som helst af ovennævnte krav, hvor antistoffet er koblet til et toksisk middel.
14. Forbindelse til anvendelse ifølge et hvilket som helst af ovennævnte krav, hvor anti-NKp46-antistoffet administreres som en farmaceutisk acceptabel sammensætning, der omfatter en terapeutisk effektiv mængde af anti-NKp46-antistoffet.
DK14704576.9T 2013-02-14 2014-02-13 Behandling af perifert t-cellelymfom DK2956482T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764639P 2013-02-14 2013-02-14
US201361831792P 2013-06-06 2013-06-06
PCT/EP2014/052849 WO2014125041A1 (en) 2013-02-14 2014-02-13 Treatment of peripheral t cell lymphoma

Publications (1)

Publication Number Publication Date
DK2956482T3 true DK2956482T3 (da) 2017-10-16

Family

ID=50112904

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14704576.9T DK2956482T3 (da) 2013-02-14 2014-02-13 Behandling af perifert t-cellelymfom
DK17177583.6T DK3255062T3 (da) 2013-02-14 2014-02-13 Anti-nkp46-antistof til diagnosticering af et ikke-kutant perifert t-cellelymfom (ptcl)

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17177583.6T DK3255062T3 (da) 2013-02-14 2014-02-13 Anti-nkp46-antistof til diagnosticering af et ikke-kutant perifert t-cellelymfom (ptcl)

Country Status (5)

Country Link
US (3) US10344087B2 (da)
EP (2) EP2956482B1 (da)
DK (2) DK2956482T3 (da)
ES (2) ES2747920T3 (da)
WO (1) WO2014125041A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2956482T3 (da) * 2013-02-14 2017-10-16 Innate Pharma Behandling af perifert t-cellelymfom
WO2016030488A1 (en) * 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
AU2016299166B2 (en) 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
CN115925933A (zh) * 2015-12-28 2023-04-07 依奈特制药公司 NKp46结合蛋白的可变区
CA3032249A1 (en) * 2016-08-17 2018-02-22 University Health Network Regulation of tumor-associated t cells
EP3510047A1 (en) 2016-09-07 2019-07-17 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Anti-nkp46 antibodies and therapeutic use of same
US20190248895A1 (en) 2016-10-21 2019-08-15 Innate Pharma Treatment with anti-kir3dl2 agents
WO2018138032A2 (en) * 2017-01-24 2018-08-02 Innate Pharma NKp46 BINDING AGENTS
CA3063955A1 (en) * 2017-05-19 2018-11-22 Royal Melbourne Institute Of Technology Predicting responders to cyclophosphamide therapy
CA3099308A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
AU717020B2 (en) 1996-05-03 2000-03-16 Immunomedics Inc. Targeted combination immunotherapy of cancer
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20050058661A1 (en) 2002-10-18 2005-03-17 Sykes Kathryn F. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus Borrelia
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
DE10324108B3 (de) 2003-05-21 2005-01-27 Aesculap Ag & Co. Kg Wirbelkörperersatzimplantat
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
SG173322A1 (en) 2004-04-16 2011-08-29 Macrogenics Inc Dw Us Fc gammad riib - specific antibodies and methods of use thereof
WO2005110474A2 (en) 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
US20090208500A1 (en) 2005-06-03 2009-08-20 Genentech, Inc. Method of producing antibodies with improved function
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2012202895A1 (en) * 2005-10-14 2012-06-07 Innate Pharma Compositions and methods for treating proliferative disorders
AU2006301163B2 (en) * 2005-10-14 2012-02-23 Innate Pharma Compositions and methods for treating proliferative disorders
FR2894982A1 (fr) 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
BRPI0707290A2 (pt) 2006-01-17 2011-08-16 Biolex Therapeutics Inc composições e métodos para humanização e otimização de n-glicanas em plantas
CA2644903A1 (en) 2006-03-10 2007-09-20 Macrogenics, Inc. Identification and engineering of antibodies with variant heavy chains and methods of using same
US7786270B2 (en) 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
EP2523687B1 (en) * 2010-01-15 2017-08-02 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for diagnosis and treatment of cutaneous T cell lymphomas using the NKp46 receptor
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
US20140234342A1 (en) 2011-06-21 2014-08-21 Innate Pharma Nkp46-mediated nk cell tuning
DK2956482T3 (da) * 2013-02-14 2017-10-16 Innate Pharma Behandling af perifert t-cellelymfom

Also Published As

Publication number Publication date
ES2637151T3 (es) 2017-10-11
EP3255062B1 (en) 2019-07-03
ES2747920T3 (es) 2020-03-12
EP2956482B1 (en) 2017-06-28
US20240425586A1 (en) 2024-12-26
DK3255062T3 (da) 2019-10-07
EP2956482A1 (en) 2015-12-23
EP3255062A1 (en) 2017-12-13
US10344087B2 (en) 2019-07-09
US20150376274A1 (en) 2015-12-31
US11999784B2 (en) 2024-06-04
US20190315857A1 (en) 2019-10-17
WO2014125041A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
US12084498B2 (en) Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
US20240425586A1 (en) Treatment of peripheral t cell lymphoma
US20240124579A1 (en) Kir3dl2 binding agents
WO2016030488A1 (en) Treatment of celiac disease